Key result
Biological pacing offers a potential permanent bradyarrhythmia cure with greater physiological responsiveness than electronic pacemakers.
Biological pacemakers via gene therapy represent a promising future approach for treating bradyarrhythmias with potentially greater physiological responsiveness than electronic pacemakers.
Biological pacing via gene therapy remains preclinical; leaves open clinical translation pending rigorous human trials.
Bradyarrhythmias are common and may be caused by sinus node dysfunction or conduction block. Many of these conditions can be treated by the implantation of electronic cardiac pacemakers that reduce mortality and morbidity in carefully selected patient groups. Implantable electronic pacemakers are small, sophisticated and reliable but not without complication and limitation. Efforts have been made to create a de novo sinus node using gene therapy, the so-called biopacemaker. This approach has potential as permanent cure for bradyarrythmias with greater physiological responsiveness than that provided by rate-responsive electronic pacemakers. This article reviews the current approaches to the problem and gives a perspective on the challenges remaining to bring the therapy to clinical practice.
No takes yet. Share an insight, caveat, or question.
Morris et al. (2009) conducted a review in Bradyarrhythmias. Biological pacing (gene therapy) vs. Electronic cardiac pacemakers was evaluated. Biological pacing via gene therapy is reviewed as a potential permanent cure for bradyarrhythmias, offering greater physiological responsiveness than electronic pacemakers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: